Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Now, despite playing no formal role in the battle between Pfizer and Starboard, Guggenheim has found itself in the crossfire of one of the messiest activist campaigns in recent Wall Street memory.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback